Should stereotactic ablative body radiotherapy be the standard of care in oligometastatic cancer?

Affiliations

¹ Division of Radiation Oncology, Department of Oncology, Western University, London Health Sciences Centre, London, ON N6A4L6, Canada.
² Division of Radiation Oncology, Department of Oncology, Western University, London Health Sciences Centre, London, ON N6A4L6, Canada. Electronic address: david.palma@lhsc.on.ca.

Comment

Rohann J M Correa et al. Lancet Oncol. 2021 Jan.

. 2021 Jan;22(1):6-8.

doi: 10.1016/S1470-2045(20)30633-1.

¹ Division of Radiation Oncology, Department of Oncology, Western University, London Health Sciences Centre, London, ON N6A4L6, Canada.
² Division of Radiation Oncology, Department of Oncology, Western University, London Health Sciences Centre, London, ON N6A4L6, Canada. Electronic address: david.palma@lhsc.on.ca.

No abstract available

Comment on

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.
Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N. Chalkidou A, et al. Lancet Oncol. 2021 Jan;22(1):98-106. doi: 10.1016/S1470-2045(20)30537-4. Lancet Oncol. 2021. PMID: 33387498